Programs

BTK Inhibitors for the Frontline Treatment of CLL

Dr. Laurie Sehn discusses the management of BTK-related toxicities, based on a recently published paper in Current Oncology by Dr. Laurie Sehn, Dr. Andrew Aw & Dr. Sue Robinson. Funding for the paper and WebEx were provided by AstraZeneca.

Les inhibiteurs de la BTK pour le traitement de première intention de la LLC Présentation

La Dre Inès Chamakhi discute de la prise en charge des toxicités liées aux inhibiteurs de la BTK d’après un article récemment publié dans la revue Current Oncology par la Dre Laurie Sehn , le Dr Andrew Aw et la Dre Sue Robinson. La production de ce programme de formation a été commanditée par AstraZeneca Canada Inc.

Treatment of CLl during COVID-19

Dr. Laurie Sehn discusses the treatment of CLL during the coronavirus pandemic, based on a recently published paper by Dr. Laurie Sehn, Dr. Philip Kuruvilla, and Dr. Julie Stakiw. The full paper can be found here: https://www.current-oncology.com/inde.... Funding for the paper development was provided by Janssen Canada & for the Webex by AstraZeneca Canada.

Prise en charge de la LLC au Canada pendant la pandémie de COVID-19

Dr Michel Pavic discute du traitement de la LLC à l’ère de la pandémie de Covid 19, d’après les résultats d’un article publié récemment dans la revue Current Oncology (Dre Laurie Sehn, Dr Philip Kuruvilla et Dre Julie Stakiw).

ASCO 2020: CLL Updates

Dr. Mona Shafey presents key updates on the treatment of chronic lymphocytic leukemia from the ASCO 2020 virtual Meeting.

English: NGS Guidelines

Dr. Stephen Yip, Director of the Cancer Genetics & Genomics Lab at BC Cancer in Vancouver, British Columbia, presents a summary of the first Canadian guidelines on Next Generation Sequencing (NGS). The published guidelines can be found in the April issue of Current Oncology.

FRENCH: NGS Guidelines

Dr. Patrice Desmeules, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec, QC presents a summary of the recently published Canadian guidelines on next generation sequencing (NGS).

RWE Education program_FINAL_Dec5-19_FINAL.pptx

Real-World Evidence in Inflammatory Arthritis

SCNursingProgram_Jan27_17.pptx

SC Rituximab Nursing Program

ASH 2019: CLL Updates

Dr. Versha Banerji Discusses Practice-Changing Studies in Treatment-Naive CLL.

Tel. 416-434-8923

Email. info@impactmedicom.com